Spark Therapeutics Company Profile (NASDAQ:ONCE)

About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics logoSpark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ONCE
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.47 billion
  • Outstanding Shares: 31,250,000
Average Prices:
  • 50 Day Moving Avg: $68.14
  • 200 Day Moving Avg: $60.16
  • 52 Week Range: $35.07 - $80.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.15
  • P/E Growth: -0.58
Sales & Book Value:
  • Annual Revenue: $20.36 million
  • Price / Sales: 121.19
  • Book Value: $7.31 per share
  • Price / Book: 10.80
  • EBIDTA: ($165,640,000.00)
  • Net Margins: -962.72%
  • Return on Equity: -59.74%
  • Return on Assets: -52.08%
  • Current Ratio: 6.09%
  • Quick Ratio: 6.09%
  • Average Volume: 462,131 shs.
  • Beta: 3.41
  • Short Ratio: 12.48
Frequently Asked Questions for Spark Therapeutics (NASDAQ:ONCE)

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics, Inc. (NASDAQ:ONCE) issued its earnings results on Wednesday, August, 2nd. The company reported ($1.89) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.75) by $0.14. The company earned $1.48 million during the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. Spark Therapeutics's quarterly revenue was up 14.7% on a year-over-year basis. During the same period in the prior year, the business earned ($1.04) earnings per share. View Spark Therapeutics' Earnings History.

Where is Spark Therapeutics' stock going? Where will Spark Therapeutics' stock price be in 2017?

11 brokers have issued 1-year target prices for Spark Therapeutics' stock. Their predictions range from $28.00 to $100.00. On average, they anticipate Spark Therapeutics' stock price to reach $84.55 in the next twelve months. View Analyst Ratings for Spark Therapeutics.

What are analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:

  • 1. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (8/5/2017)
  • 2. Chardan Capital analysts commented, "We continue to expect ENDP shares to be range-bound in the near to medium term. Our recent analysis of ENDP’s additional unfunded mesh liability and discussion with a legal expert familiar with mass tort/product liability defense ligation supports our view ENDP will remain highly levered (in the 4s) and the company’s turnaround will take several years. While we view any of our potential settlement scenarios for the company’s additional unfunded mesh liability to be manageable, we believe continued pricing pressure in ENDP’s US generics base business, need for additional advertising and promotion spend to support Xiaflex growth and inability to grow through meaningful acquisitions leave ENDP little room for error." (7/24/2017)
  • 3. Cantor Fitzgerald analysts commented, "2017 – Year of First Gene Therapy Approval in U.S.? Management reiterated its confidence in filing its rolling BLA in early 2017, and highlighted that the company has completed the necessary manufacturing runs to support its submission. Outstanding items for the filing include finalization of stability testing and CMC module write-up. We believe the timing of the filing could lead to the first approved gene therapy in the U.S. this year and remind investors that the FDA previously amended its granted orphan designation for voretigene neparvovec to cover inherited retinal diseases caused by biallelic RPE65 mutations." (2/23/2017)
  • 4. Stifel Nicolaus analysts commented, "Management's 4Q16 earnings announcement/call contained minimally-incremental insight on many of the data catalysts still anticipated for 1H17. We believe management's commentary around the current state of pre-commercialization activities for voretigene neparvovec (VN) ' including directionally positive feedback on both the access and reimbursement fronts ' should ameliorate some of the near-term concerns of those investors anticipating pricing/reimbursement to potentially represent a source of headline risk. We believe anticipation around a number of key near-term data catalysts ' including early-FY17 SPK-7001 data in choroideremia, updated early-April SPK-9001 data in hemophilia B, and preliminary mid-FY17 SPK-8011 data ' should keep ONCE shares at the forefront of relevancy over the coming months. Estimates largely unchanged." (2/23/2017)

Who are some of Spark Therapeutics' key competitors?

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:

  • Steven M. Altschuler M.D., Independent Chairman of the Board
  • Katherine A. High M.D., President, Chief Scientific Officer, Director
  • Jeffrey D. Marrazzo, Chief Executive Officer, Co-Founder, Director
  • Stephen W. Webster, Chief Financial Officer
  • John Furey, Chief Operating Officer
  • Joseph W. La Barge Esq., General Counsel
  • Daniel R. Faga, Chief Business Officer
  • Lars G. Ekman M.D., Ph.D., Independent Director
  • Anand Mehra M.D., Independent Director
  • Vincent J. Milano, Independent Director

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Who owns Spark Therapeutics stock?

Spark Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include TYPENEX COMPANY -INVESTMENT, LLC (9.99%), FMR LLC (15.07%), BlackRock Inc. (6.63%), Vanguard Group Inc. (6.21%), JPMorgan Chase & Co. (5.19%) and Federated Investors Inc. PA (4.38%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High, Stephen W Webster and Steven Altschuler. View Institutional Ownership Trends for Spark Therapeutics.

Who sold Spark Therapeutics stock? Who is selling Spark Therapeutics stock?

Spark Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., PointState Capital LP, Capital World Investors, State Street Corp, Wells Fargo & Company MN, Ameriprise Financial Inc., Fred Alger Management Inc. and AXA. Company insiders that have sold Spark Therapeutics stock in the last year include Anand Mehra, Barge Joseph La, Daniel Faga, Jeffrey D Marrazzo, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.

Who bought Spark Therapeutics stock? Who is buying Spark Therapeutics stock?

Spark Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., Sectoral Asset Management Inc, Vanguard Group Inc., JPMorgan Chase & Co., Citigroup Inc., Northern Trust Corp and Quantitative Investment Management LLC. View Insider Buying and Selling for Spark Therapeutics.

How do I buy Spark Therapeutics stock?

Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of Spark Therapeutics stock can currently be purchased for approximately $78.96.

MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  390
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Spark Therapeutics (NASDAQ:ONCE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $84.55 (7.07% upside)

Analysts' Ratings History for Spark Therapeutics (NASDAQ:ONCE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Evercore ISIInitiated Coverage$83.00LowView Rating Details
8/8/2017Chardan CapitalUpgradeNeutral -> Buy$60.00 -> $100.00LowView Rating Details
8/3/2017Stifel NicolausReiterated RatingBuy$77.00 -> $92.00LowView Rating Details
8/3/2017Cowen and CompanyReiterated RatingOutperform$75.00 -> $95.00LowView Rating Details
8/3/2017Jefferies Group LLCReiterated RatingBuy$85.00 -> $95.00HighView Rating Details
8/3/2017BMO Capital MarketsReiterated RatingOutperform$69.00 -> $89.00HighView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$87.00MediumView Rating Details
7/17/2017Cantor FitzgeraldSet Price TargetBuy$94.00MediumView Rating Details
6/28/2017William BlairInitiated CoverageOutperform -> OutperformHighView Rating Details
5/10/2017WedbushReiterated RatingUnderperform$28.00MediumView Rating Details
2/22/2017J P Morgan Chase & CoSet Price TargetBuy$82.00N/AView Rating Details
2/9/2017Leerink SwannInitiated CoverageOutperform -> Outperform$85.00N/AView Rating Details
7/12/2016Royal Bank Of CanadaInitiated CoverageOutperform$70.00N/AView Rating Details
6/21/2016SunTrust Banks, Inc.Boost Price TargetBuy$64.00 -> $72.00N/AView Rating Details
3/30/2016Goldman Sachs Group, Inc. (The)Initiated CoverageBuy -> Neutral$44.00N/AView Rating Details
12/24/2015WunderlichDowngradeBuy -> HoldN/AView Rating Details
10/11/2015Roth CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 8/17/2015 forward)


Earnings History for Spark Therapeutics (NASDAQ:ONCE)
Earnings by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Earnings History by Quarter for Spark Therapeutics (NASDAQ ONCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017($1.75)($1.89)$1.33 million$1.48 millionViewListenView Earnings Details
5/9/2017Q1 2017($1.36)($1.70)$1.35 million$1.27 millionViewListenView Earnings Details
2/22/2017Q416($1.12)($1.21)$1.32 million$16.30 millionViewListenView Earnings Details
11/3/2016Q316($1.01)($1.07)$1.26 million$1.30 millionViewN/AView Earnings Details
8/10/2016Q216($0.97)($1.04)$1.17 million$1.29 millionViewListenView Earnings Details
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details
3/9/2016Q415($0.73)($0.24)$1.30 million$17.20 millionViewListenView Earnings Details
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Spark Therapeutics (NASDAQ:ONCE)
2017 EPS Consensus Estimate: ($6.93)
2018 EPS Consensus Estimate: ($5.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.75)($1.32)($1.44)
Q2 20175($1.77)($1.71)($1.73)
Q3 20175($2.05)($1.75)($1.91)
Q4 20175($1.96)($1.59)($1.85)
Q1 20181($1.67)($1.67)($1.67)
Q2 20181($1.43)($1.43)($1.43)
Q3 20181($1.40)($1.40)($1.40)
Q4 20181($1.36)($1.36)($1.36)
(Data provided by Zacks Investment Research)


Dividend History for Spark Therapeutics (NASDAQ:ONCE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Spark Therapeutics (NASDAQ:ONCE)
Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 87.30%
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2017Stephen W WebsterCFOSell10,000$79.38$793,800.00View SEC Filing  
8/11/2017Jeffrey D MarrazzoCEOSell15,000$75.10$1,126,500.00View SEC Filing  
8/2/2017Jeffrey D MarrazzoCEOSell28,650$80.01$2,292,286.50View SEC Filing  
7/31/2017Stephen W WebsterCFOSell2,337$71.12$166,207.44View SEC Filing  
7/25/2017Katherine A HighInsiderSell10,000$72.53$725,300.00View SEC Filing  
7/24/2017Anand MehraDirectorSell211,858$70.15$14,861,838.70View SEC Filing  
7/24/2017Daniel FagaInsiderSell3,000$70.00$210,000.00View SEC Filing  
7/5/2017Jeffrey D MarrazzoCEOSell5,669$65.00$368,485.00View SEC Filing  
6/29/2017Daniel FagaInsiderSell4,500$62.71$282,195.00View SEC Filing  
6/27/2017Katherine A HighInsiderSell10,000$60.96$609,600.00View SEC Filing  
6/21/2017Anand MehraDirectorSell6,302$65.00$409,630.00View SEC Filing  
6/21/2017Jeffrey D MarrazzoCEOSell9,331$65.00$606,515.00View SEC Filing  
6/19/2017Katherine A HighInsiderSell10,000$60.00$600,000.00View SEC Filing  
6/19/2017Stephen W WebsterCFOSell7,663$60.00$459,780.00View SEC Filing  
6/7/2017Barge Joseph LaGeneral CounselSell5,000$55.00$275,000.00View SEC Filing  
4/25/2017Katherine A HighInsiderSell15,000$55.33$829,950.00View SEC Filing  
4/25/2017Stephen W WebsterCFOSell10,000$55.18$551,800.00View SEC Filing  
4/24/2017Katherine A HighInsiderSell2,060$55.01$113,320.60View SEC Filing  
4/24/2017Stephen W WebsterCFOSell1,898$55.00$104,390.00View SEC Filing  
4/3/2017Barge Joseph LaGeneral CounselSell5,000$52.73$263,650.00View SEC Filing  
3/1/2017Anand MehraDirectorSell84,654$65.02$5,504,203.08View SEC Filing  
3/1/2017Barge Joseph LaGeneral CounselSell5,000$64.41$322,050.00View SEC Filing  
2/28/2017Anand MehraDirectorSell25,274$65.02$1,643,315.48View SEC Filing  
2/27/2017Anand MehraDirectorSell41,910$65.02$2,724,988.20View SEC Filing  
2/16/2017Anand MehraDirectorSell35,347$65.03$2,298,615.41View SEC Filing  
2/7/2017Anand MehraDirectorSell25,334$65.06$1,648,230.04View SEC Filing  
12/16/2016Anand MehraDirectorSell349,656$53.46$18,692,609.76View SEC Filing  
12/15/2016Barge Joseph LaInsiderSell3,000$52.98$158,940.00View SEC Filing  
12/13/2016Anand MehraDirectorSell122,532$55.17$6,760,090.44View SEC Filing  
11/14/2016Katherine A HighInsiderSell10,000$60.30$603,000.00View SEC Filing  
10/17/2016Jeffrey D MarrazzoCEOSell5,000$54.66$273,300.00View SEC Filing  
10/3/2016Barge Joseph LaInsiderSell3,000$60.14$180,420.00View SEC Filing  
9/16/2016Jeffrey D MarrazzoCEOSell10,000$62.68$626,800.00View SEC Filing  
9/15/2016Katherine A HighInsiderSell10,000$60.37$603,700.00View SEC Filing  
8/16/2016Hospital Of Philade Children'sDirectorSell1,000,000$60.90$60,900,000.00View SEC Filing  
8/11/2016Anand MehraDirectorSell29,963$60.13$1,801,675.19View SEC Filing  
8/11/2016Jeffrey D MarrazzoCEOSell16,970$60.04$1,018,878.80View SEC Filing  
8/10/2016Katherine A HighInsiderSell1,890$60.00$113,400.00View SEC Filing  
8/8/2016Anand MehraDirectorSell100$60.47$6,047.00View SEC Filing  
8/8/2016Jeffrey D MarrazzoCEOSell900$60.24$54,216.00View SEC Filing  
8/8/2016Katherine A HighInsiderSell500$60.24$30,120.00View SEC Filing  
8/4/2016Anand MehraDirectorSell5,064$60.00$303,840.00View SEC Filing  
8/3/2016Jeffrey D MarrazzoCEOSell16,530$60.02$992,130.60View SEC Filing  
8/3/2016Katherine A HighInsiderSell17,610$60.02$1,056,952.20View SEC Filing  
8/1/2016Anand MehraDirectorSell22,665$60.03$1,360,579.95View SEC Filing  
8/1/2016Jeffrey D MarrazzoCEOSell12,348$60.03$741,250.44View SEC Filing  
8/1/2016Katherine A HighInsiderSell13,983$60.02$839,259.66View SEC Filing  
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00View SEC Filing  
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.00View SEC Filing  
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.00View SEC Filing  
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.00View SEC Filing  
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00View SEC Filing  
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00View SEC Filing  
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.00View SEC Filing  
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.00View SEC Filing  
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00View SEC Filing  
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.00View SEC Filing  
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.90View SEC Filing  
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.00View SEC Filing  
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00View SEC Filing  
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00View SEC Filing  
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00View SEC Filing  
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00View SEC Filing  
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00View SEC Filing  
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00View SEC Filing  
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.00View SEC Filing  
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.00View SEC Filing  
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.00View SEC Filing  
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Spark Therapeutics (NASDAQ:ONCE)
Latest Headlines for Spark Therapeutics (NASDAQ:ONCE)
DateHeadline logoSpark Therapeutics, Inc. (ONCE) Research Coverage Started at Evercore ISI - August 16 at 6:58 PM logoSpark Therapeutics, Inc. (ONCE) CEO Sells $1,126,500.00 in Stock - August 15 at 7:18 PM logoInsider Selling: Spark Therapeutics, Inc. (ONCE) CFO Sells 10,000 Shares of Stock - August 15 at 7:18 PM logoEdited Transcript of ONCE earnings conference call or presentation 2-Aug-17 12:30pm GMT - August 13 at 7:48 PM logoSpark Therapeutics Recognized as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal - August 12 at 6:36 AM logoCHOP spinout Spark completes $402M stock sale - August 11 at 7:16 AM logoSpark Therapeutics, Inc. Forecasted to Earn FY2017 Earnings of ($7.84) Per Share (NASDAQ:ONCE) - August 10 at 10:42 AM logoSee what the IHS Markit Score report has to say about Spark Therapeutics Inc. - August 10 at 6:30 AM logoSpark Therapeutics Announces Closing of Public Offering - August 10 at 6:30 AM logoWhy You Shouldn't Fear Spark Therapeutics' Upcoming Share Issue - Motley Fool - August 9 at 6:07 AM logoSpark Therapeutics, Inc. (ONCE) Raised to Buy at Chardan Capital - August 8 at 8:24 PM logoSpark Therapeutics, Inc. (ONCE) Given Average Rating of "Buy" by Analysts - August 8 at 4:52 PM logo Brokerages Anticipate Spark Therapeutics, Inc. (NASDAQ:ONCE) Will Post Quarterly Sales of $1.38 Million - August 8 at 7:34 AM logoWhy You Shouldn't Fear Spark Therapeutics' Upcoming Share Issue - August 7 at 8:19 AM logoQ3 2017 EPS Estimates for Spark Therapeutics, Inc. Lowered by Analyst (ONCE) - August 7 at 7:34 AM logo-$1.91 EPS Expected for Spark Therapeutics, Inc. (NASDAQ:ONCE) This Quarter - August 6 at 6:08 PM logoSpark Therapeutics, Inc. (ONCE) Lowered to "Sell" at Zacks Investment Research - August 6 at 8:56 AM logoSpark Therapeutics Prices Offering At $76/Share - August 5 at 5:29 AM logoJeffrey D. Marrazzo Sells 28,650 Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) Stock - August 4 at 4:30 PM logoSpark Therapeutics, Inc. (NASDAQ:ONCE) Forecasted to Earn Q3 2017 Earnings of ($1.89) Per Share - August 4 at 7:22 AM logoSpark Therapeutics, Inc. (ONCE) to Post Q3 2017 Earnings of ($1.96) Per Share, Leerink Swann Forecasts - August 4 at 7:22 AM logoSpark Therapeutics, Inc. to Post Q3 2017 Earnings of ($2.05) Per Share, Jefferies Group Forecasts (NASDAQ:ONCE) - August 4 at 7:22 AM logoSpark Therapeutics' (ONCE) CEO Jeff Marrazzo on Q2 2017 Results - Earnings Call Transcript - August 4 at 6:40 AM logoSpark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress - August 4 at 6:40 AM logoIllumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers - August 4 at 6:40 AM logoHere's Why Spark Therapeutics Inc. Is Soaring Today - August 4 at 6:40 AM logoSpark Therapeutics Announces Pricing of $350.0 Million Public Offering - August 4 at 6:40 AM logoSpark Therapeutics' (NASDAQ:ONCE) Buy Rating Reiterated at Jefferies Group LLC - August 3 at 8:32 PM logoCowen and Company Reaffirms "Outperform" Rating for Spark Therapeutics, Inc. (ONCE) - August 3 at 7:56 PM logoSpark Therapeutics' (NASDAQ:ONCE) Buy Rating Reiterated at Stifel Nicolaus - August 3 at 7:54 PM logoSpark Therapeutics' (ONCE) Buy Rating Reaffirmed at UBS AG - August 3 at 9:12 AM logoSpark Therapeutics reports 2Q loss - Yahoo News - August 3 at 6:35 AM logoHere's Why Spark Therapeutics Inc. Is Soaring Today - Motley Fool - August 3 at 6:35 AM logoSpark Therapeutics Announces Proposed Public Offering of Common Stock - August 3 at 6:35 AM logoSpark Therapeutics reports 2Q loss - August 3 at 6:35 AM logoStephen W. Webster Sells 2,337 Shares of Spark Therapeutics, Inc. (ONCE) Stock - August 2 at 8:34 PM logoSpark Therapeutics, Inc. (ONCE) Announces Quarterly Earnings Results - August 2 at 3:04 PM logoSpark Therapeutics, Inc. (NASDAQ:ONCE) Stock Rating Upgraded by Chardan Capital - August 2 at 1:08 PM logoSpark Therapeutics, Inc. (ONCE) Stock Rating Upgraded by BMO Capital Markets - August 2 at 1:08 PM logoSpark Therapeutics (ONCE) MMA to European Medicines Agency ... - - August 1 at 5:29 AM logoSpark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA™ (voretigene neparvovec) - August 1 at 12:26 AM logoSpark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA(TM) (voretigene neparvovec) - August 1 at 12:26 AM logoCompany Spotlight: Spark Therapeutics - July 30 at 7:50 PM logoSpark Therapeutics to Host Conference Call on Wednesday, Aug. 2 at 8:30 a.m. ET to Discuss Second Quarter 2017 Results - July 29 at 6:04 AM logoSpark Therapeutics, Inc. (NASDAQ:ONCE) Insider Sells $210,000.00 in Stock - July 26 at 8:22 PM logoKatherine A. High Sells 10,000 Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) Stock - July 26 at 7:58 PM logoInsider Selling: Spark Therapeutics, Inc. (ONCE) Director Sells 211,858 Shares of Stock - July 26 at 7:16 PM logoChardan Capital Reiterates Neutral Rating for Spark Therapeutics, Inc. (ONCE) - July 24 at 10:06 AM logoSpark Therapeutics (ONCE) Receives FDA Rare Pediatric Disease ... - - July 21 at 5:37 AM logoSpark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA™ (voretigene neparvovec) from FDA - July 21 at 5:37 AM



Spark Therapeutics (ONCE) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by Staff